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Abstract
Introduction: Prenatal screening and diagnosis is important for the detection of birth defects and genetic diseases. The nationwide proficiency 
testing (PT) of maternal serum prenatal screening in second trimester in China has been launched since 2003 and partly reflected the performance 
of screening laboratories. This study analysed the 2015 PT results to examine the performance of clinical laboratories and different platforms.
Materials and methods: Fifteen lyophilized samples with different concentrations divided into three panels, were distributed to 613 clinical labo-
ratories in 2015. Acceptable performance was defined as scores more than 80% of acceptable responses with the evaluation criterion of ± 30%. The 
robust coefficient of variation (CV) was also analysed. Chi-square (χ2) test was used to compare the acceptable performance while Kruskal-Wallis test 
and Mann-Whitney test were applied to compare the robust CV among analytes and mainstream platforms.
Results: Overall, 605, 61, 214, 416, 303 laboratories submitted effective results for alpha fetoprotein (AFP), total human chorionic gonadotropin (t-
hCG), β-hCG, unconjugated estriol (uE3) and free β-hCG. The acceptable performances of AFP (μg/L), AFP (KIU/L), t-hCG, β-hCG, uE3, and free β-hCG 
were 98.45%, 99.24%, 95.58%, 98.72%, 94.50%, and 98.66%, respectively. The χ2 test indicated significant differences existed in the acceptable 
performances among different analytes and platforms for uE3. Kruskal-Wallis test and Mann-Whitney test suggested the robust CV differed signi-
ficantly in different analytes and platforms.
Conclusions: The majority of results were acceptable. However, further effort is needed to achieve the standardization and harmonization among 
analytes and various platforms, particularly for uE3.
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The high prevalence of birth defects and genetic 
diseases in China has seriously threatened the 
health condition of neonates and affected the 
quality of population (1). The objective of prenatal 
screening and diagnosis is to identify those wom-
en at the increased risk for an affected pregnancy 
and to maximize the options available to them (2). 
Maternal serum prenatal screening in second tri-
mester is a screening test that collects the periph-
eral blood of pregnant women at 15-20 weeks (+ 6 
days), combining the age-related risk of maternal 
for an affected pregnancy with the risks associat-
ed with the concentrations of biomarkers (3). The 
serum biomarkers involves alpha fetoprotein 
(AFP), total human chorionic gonadotropin (t-hCG), 
β-hCG, unconjugated estriol (uE3), free-β-hCG, 
and Inhibin-A (Inh-A), which have been used in 
combined forms to produce double (AFP and 
t-hCG/β-hCG/free β-hCG), triple (AFP, uE3, and 
t-hCG/β-hCG/free β-hCG) and quadruple (AFP, uE3, 
Inh-A, and t-hCG/β-hCG/free β-hCG) tests (4). Sec-
ond trimester prenatal screening is economic, sim-
ple and non-invasive, and has been widely adopt-
ed since 1990s (5). 
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Prenatal screening has been started with import-
ed software in China since 1990s (6). After two 
decades, most clinical laboratories and maternal 
and childcare service centres have provided pre-
natal screening services. To ensure the reliability of 
screening testing results in second trimester and 
assess the performance of laboratories simultane-
ously, the National Center for Clinical Laboratories 
(NCCL) in China has initiated the proficiency test-
ing (PT) schemes for prenatal screening in second 
trimester nationwide since 2003, including AFP, 
hCG, β-hCG, free β-hCG and uE3. The frequency of 
PT evolves from once a year, twice a year to three 
times a year in 2015, shortening the monitoring 
period of institutions. The number of participants 
has increased from dozens to more than 600, cov-
ering 31 provinces nationwide (6). Information ob-
tained from PT scheme can partly reflect the qual-
ity of screening laboratories by comparing its re-
sults with those of its peer group that have adopt-
ed the same platform (7). In addition, extensive re-
sults from the national PT may offer valuable infor-
mation on the overall performance of prenatal 
screening laboratories within a country. This study 
presents the PT results of maternal serum prenatal 
screening in second trimester in 2015, in order to 
examine the performance of clinical laboratories 
and different platforms in China.
Materials and methods
Materials
The PT samples were commercial controls pur-
chased from Baorong (Hangzhou, China) and pre-
pared from human serum with additives of human 
or animal origin, chemicals, and stabilizers. All 
samples had been prepared, labelled and inspect-
ed to be non-reactive for the hepatitis B surface 
antigen (HBsAg), hepatitis C virus antibody (HCV) 
and human immunodeficiency virus antibody 
(HIV-1, HIV-2). All samples were provided in lyophi-
lized form to increase the stability and would re-
main stable if stored integral at 2 to 8 °C until the 
expiration date. The homogeneity and stability of 
all samples were validated based on the China Na-
tional Accreditation Service for Conformity Assess-
ment (CNAS) guidance CNAS-GL03 (8). In this sur-
vey, three PT test panels (20151, 20152, and 20153) 
consisting of fifteen samples were distributed to 
each participated laboratories in 2015, including 
low, normal, high and clinically important decision 
levels of analytes. Each sample of this PT scheme 
included five analytes: AFP, t-hCG, β-hCG, free 
β-hCG and uE3, respectively and was coded with 
six digits to facilitate analysis. The first four digits 
indicated the year, the fifth digit represented the 
lot of the panel, and the last digit stated the num-
ber of a sample in one panel. 
PT program organization
In total, 613 laboratories in China were invited to 
participate in this survey for prenatal screening or-
ganized by NCCL in 2015. Fifteen control materials 
of three panels were assigned to participated lab-
oratories in February 2015. Detailed instructions 
were provided to laboratories in hospital and ma-
ternal and child care service centres meanwhile, 
including details relating to the storage condi-
tions, sample processing methods, and other pro-
cedures. Participants were required to handle the 
samples as guided and treat them equally as the 
patient specimens according to instructions. Par-
ticipants were recommended to assay the first five 
samples (201511, 201512, 201513, 201514, 201515) in 
March, second five (201521, 201522, 201523, 
201524, 201525) in July and the last five (201531, 
201532, 201533, 201534, 201535) in October. Before 
testing, the lyophilized samples should be re-dis-
solved in 1mL of deionized or distilled water, and 
then placed upside-down with cover after stand-
ing at room temperature (18-25 °C) for 10 minutes. 
The results were submitted via the Clinet-EQA re-
porting system developed by NCCL (http://www.
clinet.com.cn) before November 2015. Participants 
were expected to handle the samples using their 
routine methods to ensure that the results of this 
survey can reflect the actual ability of measuring.
Evaluation of the results
The participated laboratories were classified into 
several subgroups in terms of the platforms they 
adopted. For each analyte, we merely selected the 
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mainstream platforms with N ≥ 10 laboratories for 
preliminary data investigation. Overall, seven plat-
forms were mentioned for all analytes in this 
study: Beckman (Brea, CA), Roche (Basel, Switzer-
land), Siemens DPC (München, Germany), Perki-
nElmer (Massachusetts, USA), Fenghua (Guang-
zhou, China), Darui (Guangzhou, China), Abbott 
(California, USA). The robust average of the results 
reported by all participants in a subgroup was 
considered as the assigned value, which was cal-
culated using algorithm A introduced in ISO 13528 
(9). For AFP, the result of each sample was consid-
ered acceptable if it fell in the range of ± 30% or 5 
μg/L (whichever was larger) of the assigned value, 
for t-hCG, β-hCG, uE3, and free-β-hCG, the criteri-
on was ± 30% established on the basis of the test-
ing performance in China. As for other PT pro-
grammes, participants would obtain 20 points for 
an acceptable result. When 4 or 5 acceptable re-
sults for each panel (5 samples) were reported (80 
or 100 points), the performance of this laboratory 
was determined to be satisfied. Unsatisfactory 
performance was attributed to scores below 80% 
for each analyte based on CLIA’ 88 (10). The overall 
acceptable performance of each analyte was de-
fined as (number of acceptable results) / (overall 
number of effective results). The acceptable per-
formance of each panel was calculated as the ratio 
of the number of laboratories with satisfactory 
performance of this panel divided by the total 
number of laboratories of this panel. The accepta-
ble performance of each platform was equivalent 
to the total number of laboratories with satisfac-
tory performance of this platform divided by the 
total number of laboratories of this platform. 
Statistical analysis
Data submitted by participants were calculated 
and statistic analysed via Microsoft Excel 2010 (Mi-
crosoft Inc., Redmond, Washington DC, USA), SPSS 
19.0 (SPSS Inc., Chicago, IL, USA) and Clinet-EQA 
evaluation system designed by NCCL and devel-
oped by Clinet Information Technology (Beijing, 
China). For each sample, basic statistic parameters, 
such as the number of laboratories, arithmetic 
mean, standard deviation (SD), coefficient of varia-
tion (CV), robust average, robust standard devia-
tion and robust CV were calculated and applied to 
assess the performance of screening laboratories. 
The parameters of each panel and platform were 
also analysed. To compare the acceptable perfor-
mance among different analytes and various plat-
forms, the chi-square (χ2) test was used. The non-
parametric Kruskal-Wallis (K-W) test and Mann-
Whitney (M-W) test were also applied to identify 
significant differences of robust CV among various 
platforms and analytes. P < 0.05 was defined as 
the threshold of significance.
Results
In 2015, a total of 613 screening laboratories in 
hospitals and maternal and child health centres 
providing prenatal screening services were en-
rolled in this PT programme, in which 605 labora-
tories submitted effective results. Results of AFP 
were submitted by two different units, μg/L and 
KIU/L, respectively. Overall, 289, 316, 61, 214, 416, 
303 laboratories submitted effective results for 
AFP (μg/L), AFP (KIU/L), t-hCG, β-hCG, uE3, and 
free-β-hCG. The overall acceptable performances 
of AFP (μg/L), AFP (KIU/L), t-hCG, β-hCG, uE3, and 
free β-hCG were 98.45%, 99.24%, 95.58%, 98.72%, 
94.50%, and 98.66%, respectively. The results of 
each screening laboratories were scored and ana-
lysed in accordance with the criteria described 
above. Table 1 shows the acceptable performance 
of three panels for each analyte in 2015. For all an-
alytes and panels, the proportion of laboratories 
with acceptable performance was above 90%, 
ranged from 92.8% (uE3, panel 20151) to 99.7% 
(AFP, KIU/L, panel 20153). The results of (χ2) test 
suggested significant differences existed in the ac-
ceptable performance among different analytes (P 
< 0.001). 
To further investigate the acceptable performance 
of different platforms, mainstream platforms with 
N ≥ 10 laboratories of each analyte were merely 
selected for data investigation (Table 2). There 
were three or two mainstream platforms for each 
of these biomarkers. The acceptable performance 
ranged from 93.0% (uE3, Beckman) to 100% (AFP: 
μg/L, DPC; t-hCG, Beckman; β-hCG, Abbott). The χ2 
test showed that the acceptable performance dif-
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Analyte (units) Panel ID Number oflaboratories


















































































AFP - alpha fetoprotein; t-hCG - total human chorionic gonadotropin; β-hCG - β-human chorionic gonadotropin; uE3 - 
unconjugated estriol; free-β-hCG - free β-human chorionic gonadotropin.
*The acceptable performance (%) of each panel was equivalent to the number of laboratories with acceptable performance of this 
panel divided by the total number of laboratories. Acceptable performance was attributed to scores ≥ 80. Acceptable result fell in 
the range of ± 30% or 5 μg/L (whichever was larger) of the assigned value, ± 30% for hCG, β-hCG, uE3, and free-β-hCG. 
Table 1. Acceptable performance for three panels in 2015
fered significantly among the mainstream plat-
forms for uE3 (P < 0.001), but not for AFP (μg/L, P = 
1.000), AFP (KIU/L, P = 0.184), t-hCG (P = 1.000), 
β-hCG (P = 0.417), and free β-hCG (P = 0.183). 
The scatter diagram of robust CV of each sample 
for 6 analytes is shown in Figure 1. Each data point 
identified the robust CV of each sample (15 sam-
ples for each analyte). AFP and free-β-hCG showed 
better performance with robust CV below 10% 
while uE3 represented a poor performance with 
robust CV reached 30%. The results of Kruskal-
Wallis test indicated statistical significant differ-
ences of robust CV from different analytes (P < 
0.001). 
To further evaluate the robust CV of different plat-
forms in prenatal screening testing, Figure 2 shows 
the assigned value (robust average), robust SD and 
robust CV for each sample and each mainstream 
platform for AFP (μg/L), AFP (KIU/L), t-hCG, β-hCG, 
uE3, and free β-hCG. The samples in horizontal 
Figure 1. The robust CV of each PT sample for 6 analytes
AFP - alpha fetoprotein; t-hCG - total human chorionic gonado-
tropin; β-hCG - β-human chorionic gonadotropin; uE3 - uncon-
jugated estriol; free-β-hCG - free β-human chorionic gonado-
tropin.



















axis were ordered by the increased concentration, 
and error bar represented the robust SD of each 
sample.
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For AFP (μg/L), the robust CV was higher in lower 
concentrations. For AFP (KIU/L), large fluctuations 
were seen in robust CV of Fenghua, while Perki-
nElmer had a preferable performance with robust 
CV below 4%. For t-hCG, the robust CV using Beck-
man was lower than that using DPC, except lots 
201511, 201533, and 201534. The robust CV did not 
change drastically with the change of assigned 
value. For β-hCG, Abbott showed best among 
these three measurement systems. For uE3, the re-
sults indicated an observable decrease in robust 
CV along with the increased concentration. The ro-
bust CV was extremely large for uE3, however, the 
robust CV of PerkinElmer was relatively low with 
robust CV less than 10%. For free-β-hCG, the ro-
bust CV had larger degree of dispersion in lower 
concentrations among different platforms. The P 
values of Kruskal-Wallis test indicated the robust 
CV differed significantly among various platforms 
for AFP (μg/L, P < 0.001), AFP (KIU/L, P < 0.001), 
β-hCG (P < 0.001), uE3 (P < 0.001), and free-β-hCG 
(P = 0.002). Mann-Whitney test showed significant 
differences in robust CV between the two main-
stream platforms for t-hCG (P = 0.002).
Discussion
Clinical laboratories desire to perform well and are 
required to participate PT schemes regularly by 
national standard and some local regulations in 
China. This report is an inaugural analysis of the 
national PT scheme for maternal serum prenatal 
screening in China. Information obtained from this 
PT programme might encourage participants to 
make effort to investigate the failures and improve 
the prenatal screening testing performance in Chi-
Analyte (units) Platform Number of panels reported effective results





Beckman 491 488 99.39
Roche 141 140 99.29
DPC 66 66 100.00
AFP (KIU/L)
PerkinElmer 588 586 99.66
Fenghua 178 177 99.44
Darui 59 58 98.31
t-hCG (IU/L)
DPC 104 100 96.15
Beckman 17 17 100.00
β-hCG (IU/L)
Beckman 466 463 99.36
Roche 121 119 98.35
Abbott 26 26 100.00
uE3 (nmol/L)
Beckman 497 462 92.96
PerkinElmer 428 425 99.30
DPC 97 95 97.94
free-β-hCG (μg/L)
PerkinElmer 589 587 99.66
Fenghua 178 177 99.44
Darui 59 58 98.31
AFP - alpha fetoprotein; t-hCG - total human chorionic gonadotropin; β-hCG - β-human chorionic gonadotropin; uE3 - 
unconjugated estriol; free-β-hCG - free β-human chorionic gonadotropin.
*The acceptable performance (%) of each platform was defined as the total number of laboratories with acceptable performance 
of this platform in three panels divided by the total number of laboratories. Acceptable performance was attributed to scores ≥ 80. 
Acceptable result fell in the range of ± 30% or 5 μg/L (whichever was larger) of the assigned value, ± 30% for hCG, β-hCG, uE3, and 
free-β-hCG.
Table 2. Acceptable performance for each platform of three panels in 2015.
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Figure 2. The robust average of concentration and robust CV of each PT sample of each platform 
AFP - alpha fetoprotein; t-hCG - total human chorionic gonadotropin; β-hCG - β-human chorionic gonadotropin; uE3 - unconjugated 
estriol; free-β-hCG - free β-human chorionic gonadotropin.











































































































































































































































































































































































































































































































Robust CV of Beckman Robust CV of Roche Robust CV of DPC
PerkinElmer Fenghua Darui
Robust CV of PerkinElmer Robust CV of Fenghua Robust CV of Darui
Roche Beckman Abbott
Robust CV of Roche Robust CV of Beckman Robust CV of Abbott
PerkinElmer Fenghua Darui
Robust CV of PerkinElmer Robust CV of Fenghua Robust CV of Darui
Beckman PerkinElmer DPC
Robust CV of Beckman Robust CV of PerkinElmer Robust CV of DPC
Beckman DPC
Robust CV of Beckman Robust CV of DPC
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na, which could help to the detection of birth de-
fects and decrease the rates of birth defects ulti-
mately.
A total of 605 laboratories in tertiary and second-
ary hospitals submitted effective results, covering 
mainstream platforms used nowadays. The num-
bers of laboratories participated in different meas-
urements varied due to the disparity of selected 
screening protocols by laboratories (double, triple, 
or quadruple tests). Among them, AFP, β-hCG, 
free-β-hCG, and uE3 were customary chosen by 
laboratories while the number of laboratories us-
ing hCG was relative small (approximately selected 
by 10% laboratories). As the study for prenatal 
screening suggested that free-β-hCG was defined 
as an indicator with higher specificity in prenatal 
screening than hCG at 14 ~ 16 weeks during preg-
nancy (11).
College of American Pathologists (CAP) set the 
evaluation criterion as ± 3 standard deviations of 
the assigned value for AFP, t-hCG, uE3, and free-β-
hCG. In our study, the acceptable criterion was de-
fined as ± 30% or 5 μg/L (whichever was larger) of 
the assigned value for AFP, ± 30% for hCG, β-hCG, 
uE3, and free-β-hCG. The evaluation criterion was 
established based on the state-of-the-art perfor-
mance in China, comprehensively considering the 
suggestions from extensive specialists of labora-
tory medicine and clinical medicine. Despite the 
criterion used in this study was different from the 
criteria in other PT schemes, it can certainly reveal 
the performance of laboratories in China. 
The results of this study demonstrated that there 
was a significant difference in acceptable perfor-
mance among different analytes, in which uE3 was 
comparatively lower. Study conducted by Lü dis-
covered that the stability of uE3 was relatively 
worse than that of other measurements in prena-
tal screening (12). Likewise, our report showed the 
robust CV of uE3 was higher than that of other an-
alytes, suggesting the results of samples for uE3 
may be more possible to exceed the evaluation 
criterion, which contributed to the lower accepta-
ble performance for uE3.
The acceptable performance of maternal serum 
prenatal screening in this study differed significant 
among different platforms for uE3, but not for oth-
er analytes. The robust CV of uE3 using Beckman 
and PerkinElmer platforms was remarkably higher 
than that using DPC platform, suggesting that the 
dispersions of results using Beckman and Perki-
nElmer platforms were greater than using DPC 
platforms, thus corresponded to the lower accept-
able performance. To further analyse the root 
causes, the different performance among various 
platforms for uE3 might be explained as the prob-
lems of methodology, instructions, practice, re-
porting, or even aware of quality control of labora-
tory staff. For AFP, t-hCG, β-hCG, and free β-hCG, 
although variations within various platforms gen-
erated discrepancies, and significant differences 
existed in the robust CV among different plat-
forms, the acceptable performance had no signifi-
cant statistical difference among those platforms.
A limitation of this study was the manufacture, 
transport, and storage technique of control mate-
rials, and simulated mature sera instead of sam-
ples of real pregnant women were used in the PT 
scheme, which may have caused the unavoidable 
matrix effect. There might be a significant differ-
ence among results of different platforms due to 
the matrix effect, so the assigned value (robust av-
erage) was also calculated by subgroups. In spite 
of this, the performance in the PT scheme could 
somewhat reflect the performance of daily prac-
tice in laboratories and platforms. 
In conclusion, the results of this prenatal screening 
PT scheme indicated that the majority of results 
were acceptable in maternal serum prenatal 
screening in second trimester in China. However, 
significant difference existed in the acceptable 
performance among analytes and platforms for 
uE3. The PT scheme is vital, and further effort is 
needed to achieve the standardization and har-
monization among various platforms, particularly 
for uE3.
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